echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Lucaparib as an Alternative to Chemotherapy for BRCA1/2 Mutant Recurrent Ovarian Cancer

    Lancet Oncol: Lucaparib as an Alternative to Chemotherapy for BRCA1/2 Mutant Recurrent Ovarian Cancer

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    There are few prospective studies comparing the efficacy of PARP inhibitors with chemotherapy in BRCA1 or BRCA2 mutated ovarian cancer
    .


    The aim of this study was to evaluate the efficacy of the PARP inhibitor lucaparib versus platinum-based and non-platinum-based chemotherapy in BRCA1/2-mutated ovarian cancer


    To evaluate the efficacy of the PARP inhibitor lucaparib versus platinum-based and non-platinum-based chemotherapy in BRCA1/2-mutated ovarian cancer


    This is an open-label, randomized, controlled Phase 3 study (ARIEL4) in 64 hospitals and cancer centers in multiple countries, recruiting BRCA1 or BRCA2 mutations in patients 18 years of age and older who have received at least 2 prior chemotherapy treatments of ovarian cancer patients
    .


    Patients were randomized (2:1) to receive oral lucaparib (600 mg, 2/day) or chemotherapy


    In the efficacy analysis population, progression-free survival in both groups

    In the efficacy analysis population, progression-free survival in both groups

    Between March 1, 2017, and September 24, 2020, a total of 930 patients were screened, of whom 349 eligible patients (median age 58 years, 95% white) were randomized to lucapa benefit group (n=233) or chemotherapy group (n=116)
    .


    As of September 30, 2020, the median follow-up was 25.


    In the efficacy analysis population (220 in the rucaparib group and 105 in the chemotherapy group), the median progression-free survival was 7.


    In the intention-to-treat population, progression-free survival in both groups

    In the intention-to-treat population, progression-free survival in both groups

    The most common adverse reactions requiring urgent treatment were grade 1/2
    .


    The most common grade 3 or higher adverse reactions were anemia or hemoglobin reduction (lucaparib vs chemotherapy: 22% vs 5%)


    The most common adverse reactions of grade 3 and above are anemia or decreased hemoglobin The most common adverse reactions of grade 3 and above are anemia or decreased hemoglobin

    Taken together, the results of the ARIEL4 study support lucaparib as an alternative treatment option for chemotherapy in recurrent, BRCA1- or BRCA2-mutated ovarian cancer


    Lucaparib as an alternative to chemotherapy in recurrent, BRCA1 or BRCA2-mutated ovarian cancer Lucaparib as an alternative to chemotherapy in recurrent, BRCA1 or BRCA2-mutated ovarian cancer

     

    Original source:

    Original source:

    Rebecca Kristeleit, et al.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.